A5035058665- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Cancer Cells and Metastasis
- Hepatocellular Carcinoma Treatment and Prognosis
- Metabolomics and Mass Spectrometry Studies
- Colorectal Cancer Treatments and Studies
- Cancer, Lipids, and Metabolism
- Histone Deacetylase Inhibitors Research
- Radiomics and Machine Learning in Medical Imaging
- CAR-T cell therapy research
- Ferroptosis and cancer prognosis
- Cancer Research and Treatments
- DNA Repair Mechanisms
- Peptidase Inhibition and Analysis
Cedars-Sinai Medical Center
2022-2025
754 Background: Immunosuppressive cells (cancer-associated fibroblasts [CAFs], tumor associated neutrophils [TANs], M2/M1 macrophages) can influence CD8 + T cell infiltration in the PDAC TME. The spatial proximity of these to and association with clinical outcomes is not well known. We hypothesize distances between phenotypes: CXC chemokine receptor 4 (CXCR4) TANs, CAFs, focal adhesion kinase (FAK) cells, FAK M2 M1 macrophages will correlate survival outcomes. Methods: Twenty-two stage I/II...
Abstract Background Previous research demonstrates longer survival for patients with lung-only metastatic pancreatic adenocarcinoma (mPDAC) compared to liver-only mPDAC. The objective of this study is understand the differences, impact chemotherapy, and associated genomic features mPDAC that isolated either liver or lung. Patients methods Longitudinal clinical outcomes molecular sequencing data were retrospectively analyzed across 831 PDAC all stages whose tumors first metastasized Survival...
4164 Background: Neoadjuvant approaches are routinely used in the treatment of resectable, borderline resectable (BR) and locally advanced (LA) PDAC. However, there few predictive biomarkers response to neoadjuvant therapy potentially PDAC patients. Mutations DDR genes occur frequently PDAC; however, their implications setting remain unclear. Methods: We conducted a dual center (Cedars-Sinai MGH), matched cohort retrospective analysis patients with BR or LA without mutations ( ATM, BARD1,...
Advanced pancreatic cancer is underscored by progressive therapeutic resistance and a dismal 5-year survival rate of 3%. Preclinical data demonstrated glutamine supplementation, not deprivation, elicited antitumor effects against ductal adenocarcinoma (PDAC) alone in combination with gemcitabine dose-dependent manner. The GlutaPanc phase I trial single-arm, open-label clinical investigating the safety L-glutamine, gemcitabine, nab-paclitaxel subjects (n = 16) untreated, locally advanced...
4024 Background: PDAC is an aggressive cancer and refractory to immunotherapy due its immunosuppressive tumor microenvironment (TME). Focal adhesion kinase (FAK) a master regulator of the TME associated with immune suppression. Our current randomized phase II trial evaluates use pembrolizumab, programmed cell death 1 (PD-1) checkpoint inhibitor, or without defactinib, FAK inhibitor (FAKi), as sequential neoadjuvant adjuvant therapy in patients high risk resectable PDAC. We hypothesize that...
TPS4192 Background: PDAC is an aggressive cancer. It remains refractory to checkpoint inhibition because of its significant desmoplastic and immunosuppressive tumor microenvironment (TME). Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, involved in progression many cancers appears be targetable master regulator the TME PDAC. FAK combined with anti-PD1 antibody has been shown modulate pancreatic stellate cells decrease myeloid T-reg cells, leading increased CD8 infiltration...
532 Background: PDAC remains one of the most lethal malignancies following metastatic presentation, typically to liver or lung. Previous studies have observed that advanced patients variable outcomes depending on site involvement. Here, we aim understand survival and molecular features for based involvement lung vs liver. Methods: We retrospectively analyzed longitudinal clinical across 787 with next generation sequencing (NGS) from Perthera’s Real-World Evidence database whose tumors first...
Pancreatic metastasis of primary lung adenocarcinoma is a rare occurrence, accounting for <0.3% all pancreatic malignancies. Given that the prognosis and treatment options cancer differ greatly from metastases site, an accurate diagnosis critical. This report presents unique case 65-year-old man who was admitted with significant unintentional weight loss, fatigue, abdominal pain, jaundice, found to have mass initially thought be subsequently diagnosed as EGFR -mutated pancreas via early...
743 Background: The prognosis of metastatic pancreatic ductal adenocarcinoma (mPDAC) remains poor with a median survival time 10-12 months. First-line treatment is largely influenced by performance status fit patients more often receiving FOLFIRINOX (FFX) than Gemcitabine+Nab-Paclitaxel (GNP). Although the two regimens have improved outcomes over gemcitabine monotherapy, no biomarkers routinely used in clinical practice can predict which regimen optimal to facilitate precision medicine...
181 Background: KRAS mutations have been widely characterized as markers of poor prognosis in CRC. In stage IV CRC, are predictive benefit to anti-EGFR therapy. ctDNA has increasingly recognized a prognostic biomarker CRC well. We evaluated the association between plasma metabolites and mutation or status longitudinal, observational cohort patients with I-IV Methods: This was retrospective analysis prospectively collected blood samples from single-institute All were at pre-chemotherapy...
Abstract Background: PDAC is an aggressive and treatment-refractory cancer due to its desmoplastic immunosuppressive tumor microenvironment (TME). Overexpression of pFAK, a master regulator the TME, CXCR4, receptor involved immunosuppression progression, are associated with poorer outcomes in PDAC. Exceptional responders, broadly defined by extended survival durable treatment responses, represent rare subset We hypothesize that immune stromal signatures exceptional responders vary...
e15575 Background: Metabolomics is an evolving technique that can offer a non-invasive method for comprehensive identification of metabolic biomarkers. We evaluated the feasibility measuring plasma metabolites in longitudinal, observational cohort patients (pts) with stage I-IV CRC association disease characteristics and overall survival (OS). Methods: In this retrospective analysis prospectively collected blood samples from single-institute pts CRC, up to 150 central carbon metabolism were...
TPS636 Background: Cytotoxic chemotherapy remains the preferred first-line treatment for advanced or unresectable pancreatic cancer with combination regimens including 5-fluoruracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), gem nab-p. The use response of second- third-line therapies dismal, thus optimization is critical. Our previous work investigating Gln metabolism in ductal adenocarcinoma (PDAC) through glutaminase inhibition indicates that deprivation PDAC increases cell...
e16270 Background: PDAC is the third most fatal cancer, where patients present with metastases at diagnosis. Previous studies, including a retrospective analysis from our single-center experience, suggests survival rates are significantly higher for those lung-only (mets) when compared to liver metastasis or other sites of (liver+other). The objective this explore difference based on and impact chemotherapy national cohort. Methods: We identified (>18years) either 1) lung-only; 2)...